Phathom Pharmaceuticals, Inc.·4

Sep 26, 7:03 PM ET

Basta Steven L 4

4 · Phathom Pharmaceuticals, Inc. · Filed Sep 26, 2025

Insider Transaction Report

Form 4
Period: 2025-09-25
Basta Steven L
DirectorPresident and CEO
Transactions
  • Exercise/Conversion

    Performance Shares

    2025-09-2590,000270,000 total
    Exercise: $0.00Common Stock (90,000 underlying)
  • Exercise/Conversion

    Common Stock

    2025-09-25+90,00090,000 total
  • Tax Payment

    Common Stock

    2025-09-25$11.66/sh48,375$564,05341,625 total
Footnotes (3)
  • [F1]Represents shares underlying the performance stock units that were surrendered by the reporting person to the Issuer in satisfaction of the Issuer's tax withholding obligation.
  • [F2]Each performance stock unit represents a contingent right to receive one share of common stock of the Issuer.
  • [F3]On April 3, 2025, the reporting person was granted 360,000 performance stock units, of which 90,000 vested on September 25, 2025 due to the achievement of the applicable stock price hurdle. The remaining performance stock units will vest based on the achievement of stock price hurdles over a period of four years following the grant date, subject to the reporting person's continued service through the date each such stock price hurdle is achieved.

Documents

1 file
  • 4
    ownership.xmlPrimary

    4